TYBR Health today announced a $30 million Series A financing led by Vensana Capital and Mutual Capital Partners, with participation from Neovate Capital Partners and existing investors. The company will use the funds to expand commercial access to its FDA-cleared B3 GEL® System, broaden its product indications, and run clinical studies evaluating tissue protection during orthopedic surgery. Orthopedic surgery is very good at what it sets out to do: restore anatomy and repair